Sunesis Pharmaceuticals (SNSS) Lowered to Hold at Zacks Investment Research

Zacks Investment Research cut shares of Sunesis Pharmaceuticals (NASDAQ:SNSS) from a strong-buy rating to a hold rating in a research note released on Thursday.

According to Zacks, “Sunesis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. It has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics. It is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies. “

A number of other equities research analysts have also recently issued reports on SNSS. ValuEngine upgraded Sunesis Pharmaceuticals from a sell rating to a hold rating in a research note on Wednesday, January 2nd. HC Wainwright assumed coverage on Sunesis Pharmaceuticals in a research note on Thursday, December 20th. They issued a neutral rating and a $0.50 price objective on the stock. Four research analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. The company has an average rating of Hold and a consensus price target of $1.75.

SNSS opened at $0.73 on Thursday. The firm has a market cap of $18.33 million, a price-to-earnings ratio of -0.51 and a beta of 2.57. Sunesis Pharmaceuticals has a 1 year low of $0.20 and a 1 year high of $7.69.

Sunesis Pharmaceuticals (NASDAQ:SNSS) last posted its quarterly earnings data on Monday, November 5th. The biopharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.22) by $0.04. As a group, sell-side analysts anticipate that Sunesis Pharmaceuticals will post -0.81 earnings per share for the current fiscal year.

Sunesis Pharmaceuticals Company Profile

Sunesis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. Its lead program is vecabrutinib, a non-covalently binding inhibitor of Bruton's tyrosine kinase (BTK), which is in Phase 1b/2 clinical trial in B-cell malignancies.

Read More: What Is An Exchange-Traded Fund (ETF)?

Get a free copy of the Zacks research report on Sunesis Pharmaceuticals (SNSS)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Sunesis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit